Modifying clinical practices to manage influenza in children effectively

Pediatric Infectious Disease Journal

Volumn 27, Issue 8, 2008, Pages 738-743

  Glezen, William Paul ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Influenza in children; Prevention; Treatment

Indexed keywords

OSELTAMIVIR; RIMANTADINE; ZANAMIVIR; ANTIVIRUS AGENT; INFLUENZA VACCINE; SIALIDASE;

ABDOMINAL PAIN; AUTOMUTILATION; CHILD; CLINICAL PRACTICE; DELIRIUM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EAR DISEASE; EPISTAXIS; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS B; PRIORITY JOURNAL; REVIEW; VOMITING; ADOLESCENT; ANIMAL; CHEMOPROPHYLAXIS; DRUG ANTAGONISM; DRUG EFFECT; HOSPITALIZATION; INFANT; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H5N1; MORTALITY; NEWBORN; PRESCHOOL CHILD; STATISTICS;

ADOLESCENT; ANIMALS; ANTIVIRAL AGENTS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR;

EID: 51049101323     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31816d9299     Document Type: Review

References (50)

1. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics. 2004;113:1758-1764.
2. Glezen WP, Taber LH, Frank AL, et al. Influenza virus infections in infants. Pediatr Infect Dis J. 1997;16:1065-1068.
3. Poehling KA, Edwards KM, Weinberg GA, et al. The nderrecognized burden of influenza in young children. N Engl J Med. 2006;355:31-40.
4. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353:2559-2567.
5. Whitley RJ, Monto AS. Prevention and treatment of influenza in highrisk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis. 2006;194(Suppl 2):S133-S138.
6. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.N Engl J Med. 2000;342:225-231.
7. Glezen WP, Decker M, Joseph SW, et al. Acute respiratory disease associated with influenza epidemics in Houston, 1981-1983. J Infect Dis. 1987;155:1119-1126.
8. Neuzil KM, Wright PF, Mitchel EF Jr, et al. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000;137:856-864.
9. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007;56(RR-6):1-54.
10. Centers for Disease Control and Prevention. Influenza vaccination coverage among children aged 6-23 months-United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2007;56:959-963.
11. Santibanez TA, Santoli JM, Bridges CB, et al. Influenza vaccination coverage of children aged 6 to 23 months: the 2002-2003 and 2003-2004 influenza seasons. Pediatrics. 2006;118:1167-1175.
12. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics. 2006;118:2409-2417.
13. Coffin SE, Zaoutis TE, Rosenquist AB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics. 2007;119:740-748.
14. Centers for Disease Control and Prevention. Update: Influenza activity-United States and worldwide, 2006-07 season, and composition of the 2007-08 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2007;56: 789-794.
15. Grijalva CG, Poehling KA, Edwards KM, et al. Accuracy and interpretation of rapid influenza tests in children. Pediatrics. 2007;119:e6-e11.
16. Centers for Disease Control and Prevention. Rapid diagnostic testing for influenza: information for clinical laboratory directors. Fact sheet. Availableat:http://www.cdc.gov/flu/professionals/diagnosis/rapidlab. htm. Accessed September 27, 2007.
17. World Health Organization. WHO recommendations on the use of rapid testing for influenza diagnosis. July 2005. Available at: http://www.who.int/ csr/disease/avian-influenza/guidelines/RapidTestInfluenza-web.pdf. Accessed September 27, 2007.
18. Shuler CM, Iwamoto M, Bridges CB, et al. Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004. Pediatrics. 2007;119:e587-e595.
19. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685-696.
20. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25:870-879.
21. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860-869.
22. Ritzwoller DP, Bridges CB, Shetterly S, et al. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics. 2005;116:153-159.
23. Halloran ME, Longini IM Jr, Gaglani MJ, et al. Estimating effectiveness of trivalent, cold-adapted, influenza vaccine (CAIV-T) against influenza A(H1N1) and B using surveillance cultures. Am J Epidemiol. 2003;158: 305-311.
24. Gaglani MJ, Piedra PA, Herschler GB, et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004;158:65-73.
25. Nyquist A-C. Influenza virus mutation and transmission. Manag Care. 2007;16(Suppl 8):6-10.
26. Halloran ME, Piedra PA, Longini IM Jr, et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drifted variant, during 2003-2004. Vaccine. 2007;25:4038-4045.
27. Ong AK, Hayden FG, John F. Enders Lecture 2006: antivirals for influenza. J Infect Dis. 2007;196:181-190.
28. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133.
29. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196:249-257.
30. American Academy of Pediatrics Committee on Infectious Diseases. Antiviral therapy and prophylaxis for influenza in children. Pediatrics. 2007;119:852-860.
31. Oseltamivir Phosphate Prescribing Information. Roche Laboratories Inc.: Nutley, NJ; 2007.
32. Zanamivir Prescribing Information. GlaxoSmithKline: Research Triangle Park, NC; 2007.
33. Hedrick A, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age:a randomized controlled trial. Pediatr Infect Dis J. 2000;19:410-417.
34. Barr CE, Schulman K, Iacuzio D, et al. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin. 2007;23:523-531.
35. Govorkova EA, Ilyushina NA, Boltz DA, et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother. 2007;51:1414-1424.
36. Ilyushina NA, Bovin NV, Webster RG, et al. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006;70:121-131.
37. Ilyushina NA, Hoffmann E, Solomon R, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12:363-370.
38. Knight V, McClung HW, Wilson SZ, et al. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981;2:945-949.
39. McClung HW, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of influenza B virus infection. JAMA. 1983;249:2671-2674.
40. Gilbert BE, Wilson SZ, Knight V, et al. Ribavirin small-particle aerosoltreatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 1985;27: 309-313.
41. Kirshon B, Faro S, Zurawin RK, et al. Favorable outcome after treatment with amantadine and ribavirin in a pregnancy complicated by influenza pneumonia. A case report. J Reprod Med. 1988;33:399-401.
42. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435-1442.
43. Moscona A, Kimm-Breschkin J. News about influenza B drug resistance that cannot be ignored. JAMA. 2007;297:1492-1493.
44. World Health Organization. Regional influenza pandemic preparedness plan (2006-2008). Available at: http://www.searo.who.int/LinkFiles/Avian-Flu-SEA-CD- 148-A4.pdf. Accessed September 27, 2007.
45. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748-754.
46. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.N Engl J Med. 2000;343:1282-1289.
47. Clover RD, Crawford SA, Abell TD, et al. Effectiveness of rimantadine prophylaxis of children within families. Am J Dis Child. 1986;140:706-709.
48. Crawford SA, Clover RD, Abell TD, et al. Rimantadine prophylaxis in children: a follow-up study. Pediatr Infect Dis J. 1988;7:379-383.
49. Brewer NT, Hallman WK. Subjective and objective risk as predictors of influenza vaccination during the vaccine shortage of 2004-2005. Clin Infect Dis. 2006;43:1379-1386.
50. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007;120:e553-e564.